Pharma Videos

Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

In a Business of Biotech interview, Zevra Therapeutics CEO Neil McFarlane outlined the company’s recent rebrand from KemPharm and its sharpened focus on developing and commercializing rare‑disease therapeutics. He traced his unconventional path—from Army Reserve medic to transplant nurse practitioner—to a mission‑first leadership style that now drives Zevra’s strategic roadmap. McFarlane highlighted several levers of growth: the $150 million sale of a pediatric priority‑review voucher in April 2025, a series of targeted acquisitions that bring complementary science and commercial expertise, and the assembly of a dedicated rare‑disease sales force. He emphasized partnership with patient‑advocacy groups to shape trial design and market access, and detailed how the company is building a commercial infrastructure capable of launching ultra‑rare products globally. The interview featured vivid analogies, such as comparing biotech execution to a military field hospital operation, underscoring the importance of clear operational orders and cultural alignment in mergers. McFarlane cited the Animan acquisition as a case where shared mission and agile scientific teams created a “force multiplier,” accelerating the development of less‑invasive transplant therapies. These moves position Zevra as a potential partner of choice for larger pharma seeking rare‑disease pipelines, while the voucher proceeds provide runway for late‑stage trials. The emphasis on culture, advocacy, and focused commercialization suggests Zevra could capture a sizable share of a market that is attracting heightened investor interest and regulatory incentives.